

- Tobramycin (*Cont.*):  
 indications for, 940t  
 for infective endocarditis, 823  
 inhalation solution, for bronchiectasis prophylaxis, 1696  
 for *P. aeruginosa* infections, 808t  
 resistance to, 931t, 934, 940t  
 for sepsis/septic shock, 1757t  
 therapeutic monitoring of, 2766t
- Tocilizumab  
 action of, 372e-30, 2147  
 adverse effects of, 2147, 2147t  
 for giant cell arteritis, 2189  
 for rheumatoid arthritis, 2147, 2147t
- $\alpha$ -Tocopherol. *See also* Vitamin E  
 for lung cancer prevention, 477  
 for prostate cancer prevention, 478
- Todd's paralysis, 2542
- Toe(s)  
 gout of, 436e-2f  
 osteoarthritis of, 2229f
- Tofacitinib  
 action of, 2147  
 adverse effects of, 2147, 2147t  
 for IBD, 1962  
 for psoriatic arthritis, 2177  
 for rheumatoid arthritis, 2147, 2147t
- TOF (time-of-flight) imaging, 440e-7
- To-fro murmur, 51e-6, 51e-7f
- Togaviruses, 214e-2t, 214e-3f, 214e-4, 1305. *See also* Alphaviruses
- Togavirus infections. *See* Alphavirus (togavirus) infections
- Tolazamide, 2413
- Tolbutamide, 284, 2413
- Tolcapone, 2615, 2616t
- Tolerable upper levels, 95e-3
- Tolerance, definition of, 61, 372e-2
- Tolfenamic acid, 2592t
- Toll-like receptor (TLR) pathway deficiencies, 2106
- Toll-like receptors (TLRs)  
 in adaptive immune response, 372e-2, 372e-6t  
 in autoimmunity, 377e-1-2  
 fever and, 125  
 in glomerular disease, 1833  
 in immune response, 950  
 in inflammatory response, 145e-5, 145e-6f  
 ligands and functions of, 372e-5t  
 in platelets, 276, 742  
 in rheumatoid arthritis, 2141, 2142f  
 in sepsis and septic shock, 1752  
 signaling pathways of, 372e-5f
- Tolosa-Hunt syndrome, 207, 1352, 2650
- Tolterodine, 81, 2672
- Tolvaptan  
 adverse effects of, 302, 511  
 for hypervolemic hyponatremia, 2283  
 for polycystic kidney disease, 1853  
 for SIADH, 64e-5, 302, 511, 610, 2282
- Tonate virus, 1306t
- Tone, 154
- Tongue  
 alterations of, 241t  
 bald, 241t  
 black hairy, 240t  
 fissured (scrotal), 46e-5f, 241t  
 geographic, 46e-3f, 241t, 342f  
 microbiome of, 86e-5, 86e-6f  
 paralysis of, 2649  
 raspberry, 241t  
 strawberry, 241t  
 ulcer on, 46e-4f  
 white coated, 46e-5f. *See also* Thrush
- Tongue worms, 2747
- Tonic-clonic seizures, 2543, 2550-2551, 2551t.  
*See also* Seizure(s)
- Tonicity, 332e-9, 332e-10f
- Tonic pupil, 196
- Tonsillectomy, 230, 404
- Tonsillitis, 235
- Tonsils, orange, 1443
- Tophi, 364t, 365, 2225f
- Topiramate  
 adverse effects of, 215, 2396, 2555t, 2556, 2594t  
 for cluster headache prevention, 2595t  
 for epilepsy, 2555t, 2556  
 for hemicrania continua, 2596  
 for migraine prevention, 2594t  
 overdose/poisoning with, 473e-10t  
 for pain, 61  
 pharmacology of, 2555t  
 with phentermine, for obesity, 2396-2397, 2397t  
 for posttraumatic headache, 111  
 for PTSD, 2712  
 for raised CSF pressure headache, 110  
 for SUNCT/SUNA prevention, 2596  
 "Top of the basilar" syndromes, 2578
- Topoisomerase I (Scl-70), 103e-13, 372e-24t, 2157t
- Topoisomerase II, 103e-13
- Topoisomerase inhibitors, 103e-9-10t, 103e-13, 623, 670, 678. *See also specific drugs*
- Topoisomerase IV, 932
- Topology, of biologic system, 87e-1-2, 87e-2f
- Topotecan  
 action of, 103e-13  
 adverse effects of, 103e-10t, 103e-13  
 for Ewing's sarcoma, 119e-4  
 for lung cancer, 522  
 for ovarian cancer, 594
- TOR (target of rapamycin), 94e-5
- Toroviruses, 1286f, 1289
- Torsades de pointes. *See* Ventricular tachycardia, polymorphic
- Torsemide, 322, 1510t, 1763
- Torsin A, 2620
- Torticollis, 2620
- TOS (true neurogenic thoracic outlet syndrome), 122
- Toscana virus, 894, 1310t, 1318
- Total artificial heart (TAH), 1518
- Total-body water, 64e-4, 332e-10, 332e-10f
- Total iron-binding capacity  
 in anemia evaluation, 393  
 causes of abnormal values, 464t  
 in hypoproliferative anemia, 398, 630t  
 in iron-deficiency anemia, 627f  
 in microcytic anemia, 628t  
 normal, 397, 627  
 in nutritional assessment, 462, 464t
- Total lung capacity (TLC), 306e-1f, 306e-2, 306e-2f, 306e-5f
- Total parenteral nutrition. *See* Parenteral nutrition
- Totipotent stem cells, 454, 454f
- Touch localization test, 159
- Touch sensation, 159, 160t, 2539
- Touraine-Solente-Golé syndrome, 2244. *See also* Hypertrophic osteoarthropathy
- Tourette's syndrome, 2623
- Tourniquet, for snakebite, 2735
- Toxic adenoma, 2302-2303, 2302f
- Toxic epidermal necrolysis (TEN)  
 vs. AGEF, 382  
 clinical features of, 361, 361t, 382-383, 384t  
 drugs associated with, 361  
 drugs causing, 383  
 epidemiology of, 131t  
 etiology of, 131t  
 genetic considerations in, 378  
 immune pathways of, 378, 378t  
 nondrug causes of, 382-383, 384t  
 prevention of future episodes, 384  
 skin manifestations of  
 blistering eruptions, 382-383, 383f, 384t  
 epidermal sloughing, 25e-7f, 131t, 134  
 vs. staphylococcal scalded skin syndrome, 134, 362, 829  
 treatment of, 383
- Toxic erythema of chemotherapy, 380
- Toxic granulations, neutrophils, 415
- Toxic megacolon  
 in *Shigella* infections, 1056-1057  
 treatment of, 1058, 1953  
 in ulcerative colitis, 1953
- Toxic multinodular goiter, 2302
- Toxic oil syndrome, 2155
- Toxic shock syndrome (TSS)  
 clostridial, 991t, 994-995  
 diarrhea in, 267  
 etiology of, 782  
 focal infections and, 784  
 skin manifestations of, 362t, 363, 782, 1755  
 staphylococcal  
 clinical features of, 130t, 363, 782, 959, 959t  
 diagnosis of, 959  
 pathogenesis of, 124, 372e-19, 955, 956  
 rash in, 130t, 134  
 tampon-associated, 959  
 treatment of, 963
- streptococcal  
 case definition of, 968, 968t  
 clinical features of, 130t, 134, 363, 782, 968, 968t  
 diagnosis of, 968-969  
 epidemiology of, 130t  
 etiology of, 130t, 968-969  
 rash in, 130t, 134  
 treatment of, 965t, 969t
- Toxic sponges, 2741
- Toxidrome, 473e-1
- Toxins. *See also specific toxins*  
 bacterial, 145e-9  
 hepatic effects of, 2023, 2025t, 2026t  
 neurologic effects of, 2688t, 2689  
 pulmonary effects of, 1688t, 1691-1692, 1692t
- Toxocara canis*, 245e-3t, 765t, 1411. *See also* Larva migrans, visceral
- Toxocara cati*, 245e-3t, 765t, 1411. *See also* Larva migrans, visceral
- Toxoplasma gondii*, 245e-4t, 245e-5t, 1398-1399, 1399f
- Toxoplasma gondii* infection (toxoplasmosis), 1398  
 asymptomatic, 1401  
 in cancer patient, 488, 488t  
 clinical features of  
 cardiac, 1400, 1471t, 1561  
 chronic meningitis, 908t  
 CNS, 903, 1265-1266, 1266f, 1401-1402, 1402f  
 gastrointestinal, 1400  
 in immunocompetent patient, 1401  
 in immunocompromised patient, 1401-1402, 1402f, 1561  
 lymphadenopathy, 409, 1400, 1401  
 myelopathy, 2657  
 ocular, 40e-6f, 1400, 1402, 1404  
 pulmonary, 1400  
 renal, 1849-1850  
 weakness, 156  
 congenital, 1398, 1399-1400, 1402, 1404  
 diagnosis of, 245e-4t, 245e-5t, 245e-6, 245e-6t, 1190t, 1402-1404  
 differential diagnosis of, 1402, 1403t  
 epidemiology of, 245e-4t, 1399  
 etiology of, 1398-1399, 1399f  
 in HIV infection, 1251-1252t, 1265-1266, 1266f, 1401-1402, 1402f, 1561  
 immune response to, 1401  
 pathogenesis of, 1400  
 pathology of, 1400-1401  
 in pregnancy, 1399-1400, 1401, 1404  
 prevention of, 1404-1405  
 prophylaxis for, 925t, 1404  
 transmission of, 1399-1400  
 in transplant recipient, 920t, 921, 925t, 926  
 treatment of, 246e-12, 246e-13, 903, 1404
- TP53 gene mutations  
 in bladder cancer, 576  
 genetic testing for, 448  
 in lung cancer, 509  
 tumors associated with, 101e-6t
- tPA. *See* Alteplase (rtPA); Tissue plasminogen activator (tPA)
- TPIT gene, 2256